Roche (RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...

The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to ...

Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...

European shares jumped on Wednesday after Ukraine accepted the U.S.' proposal for a 30-day ceasefire with Russia, while ...

Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global ...

Roche has entered an exclusive collaboration and licensing agreement with Zealand Pharma under which the parties will ...

Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a ...

Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish ...

SEB Equities upgraded Zealand Pharma (ZLDPF) to Buy from Hold with an DKK 850 price target Light Up your Portfolio with Spark:Easily identify ...

Partnership includes the development of combination products, including a fixed-dose combination of petrelintide and Roche’s dual GLP-1/GIP receptor agonist, CT-388, for weight management.